In approx. 70% of PDAC patients, TP53 undergoes mainly missense mutations (www.cbioportal.org) as a late genetic event at the transition from high grade PanIN dysplasia to invasiveness during pancreatic cancer progression (35, 36). Here, TP53 is linked to pancreatic neoplasm.